Publications

Critical appraisal of Etest for the detection of fluoroquinolone resistance. by Jones RN, Erwin ME and Croco JL published in J. Antimicrob. Chemother. 1996; 38 (1): 21-25

The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance. by Jones RN published in Diagn. Microbiol. Infect. Dis. 1996; 25 (4): 153-161

Accurate characterization of ofloxacin susceptibility with Enterobacteriaceae using a modified GNS F6 card and the bioMerieux Vitek System. by Doern GV, Torres BB, Jankins M and Jones RN published in Diagn. Microbiol. Infect. Dis. 1996; 25 (3): 133-135

False resistance to metronidazole by Etest among anaerobic bacteria investigations of contributing test conditions and medium quality. by Cormican MG, Erwin ME and Jones RN published in Diagn. Microbiol. Infect. Dis. 1996; 24 (2): 117-119

Phenotypic detection of mecA-positive staphylococcal bloodstream isolates: High accuracy of simple disk diffusion tests. by Cormican MG, Wilke WW, Barrett MS, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1996; 25 (3): 107-112

Detection of extended-spectrum β-lactamase (ESBL)-producing strains by the Etest ESBL screen. by Cormican MG, Marshall SA and Jones RN published in J. Clin. Microbiol. 1996; 34 (8): 1880-1884

Re-evaluation of contemporary laboratory methods for detection of antimicrobial resistance among enterococci. by Cormican MG, Biedenbach DJ and Jones RN published in Clin. Microbiol. Infect. 1996; 1 (3): 190-194

Comparative assessment of Etest for testing susceptibilities of Neisseria gonorrhoeae to penicillin, tetracycline, ceftriaxone, cefotaxime, and ciprofloxacin: Investigation using 510(k) review criteria, recommended by the Food and Drug Administration. by Biedenbach DJ and Jones RN published in J. Clin. Microbiol. 1996; 34 (12): 3214-3217

Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolates. by Barrett MS and Jones RN published in Diagn. Microbiol. Infect. Dis. 1996; 24 (2): 113-116

National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers. by Baron EJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 21 (3): 141-151

Evaluation of Vitek and API 20S for species identification of enterococci. by Sader HS, Biedenbach D and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 22 (4): 315-319

Evaluation of S1 chromogenic cephalosporin β-lactamase disk assay tested against Gram-positive anaerobes, coagulase-negative staphylococci, Prevotella spp. and Enterococcus spp. by Marshall SA, Sutton LD and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 22 (4): 353-355

Resistance among important pathogens and the antimicrobial activity of parenteral fluoroquinolones at 43 US medical centres. by Jones RN, Kehrberg EN and Erwin ME published in Drugs 1995; 49 (Suppl 2): 179-181

Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group. by Jones RN, Sader HS, Erwin ME and Anderson SC published in Diagn. Microbiol. Infect. Dis. 1995; 21 (2): 85-93

Emerging multiply resistant enterococci among clinical isolates. II. Validation of the Etest to recognize glycopeptide-resistant strains. by Jones RN, Erwin ME and Anderson SC published in Diagn. Microbiol. Infect. Dis. 1995; 21 (2): 95-100

Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: A review. by Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 22 (1-2): 19-33

Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity. by Jones RN published in J. Chemother. 1995; 7 (Suppl 2): 7-16

Canadian ofloxacin susceptibility study: A comparative study from 18 medical centers. Canadian Ofloxacin Study Group. by Hoban DJ and Jones RN. published in Chemotherapy 1995; 41 (1): 34-38

Multicenter clinical laboratory evaluation of a β-lactamase disk assay employing a novel chromogenic cephalosporin, S1. by Doern GV, Jones RN, Gerlach EH, Washington JA, Biedenbach DJ, Brueggemann A, Erwin ME, Knapp C and Raymond J published in J. Clin. Microbiol. 1995; 33 (6): 1665-1667

Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin). by Cormican MG, Marshall SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 21 (1): 51-54

Re-evaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone-resistant isolates. by Cormican MG and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 21 (4): 227-230

Interpretive errors using an automated system for the susceptibility testing of imipenem and aztreonam. by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 21 (1): 57-60

In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against Gram-positive aerobic organisms and anaerobes. by Biedenbach DJ and Jones RN published in Antimicrob. Agents Chemother. 1995; 39 (7): 1636-1642

Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards susceptibility test methods. Quality Control Study Group. by Bale MJ, Jones RN and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1994; 19 (1): 65-68

Efficient detection and long-term persistence of the carriage of methicillin-resistant Staphylococcus aureus. by Sanford MD, Widmer AF, Bale MJ, Jones RN and Wenzel RP published in Clin. Infect. Dis. 1994; 19 (6): 1123-1128

Pulsed-field gel electrophoresis of restriction-digested genomic DNA and antimicrobial susceptibility of Xanthomonas maltophilia strains from Brazil, Switzerland and the USA. by Sader HS, Pignatari AC, Frei R, Hollis RJ and Jones RN published in J. Antimicrob. Chemother. 1994; 33 (3): 615-618

Evaluation of interhospital spread of methicillin-resistant Staphylococcus aureus in Sao Paulo, Brazil, using pulsed-field gel electrophoresis of chromosomal DNA. by Sader HS, Pignatari AC, Hollis RJ and Jones RN published in Infect. Control Hosp. Epidemiol. 1994; 15 (5): 320-323

Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the United States. II. Study of the intra- and interlaboratory dissemination of extended- spectrum β-lactamase-producing Enterobacteriaceae. by Sader HS, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1994; 20 (4): 203-208

Cefquinome (HR 111V). In vitro evaluation of a broad-spectrum cephalosporin indicated for infections in animals. by Murphy SP, Erwin ME and Jones RN published in Diagn. Microbiol. Infect. Dis. 1994; 20 (1): 49-55

North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group. by Jones RN and Hoban DJ published in Diagn. Microbiol. Infect. Dis. 1994; 18 (1): 49-56

Interpretive criteria for DU-6859a disk diffusion tests using 5- micrograms disks. by Jones RN, Johnson DM and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1994; 18 (2): 125-127

Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. National Committee for Clinical Laboratory Standards. by Jones RN, Doern GV, Gerlach EH, Hindler J and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1994; 18 (4): 243-249

Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: Real or perceived? Fluoroquinolone Resistance Surveillance Group. by Jones RN, Kehrberg EN, Erwin ME and Anderson SC published in Diagn. Microbiol. Infect. Dis. 1994; 19 (4): 203-215

Update of lomefloxacin in vitro activity and spectrum. A multicenter trial testing contemporary pathogens following Food and Drug Administration validation guidelines. Lomefloxacin Activity Study Group. by Jones RN, Sader HS and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1994; 20 (2): 93-98

Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results. by Jones RN, Sutton LD, Cantrell HF and Lankford RB published in Diagn. Microbiol. Infect. Dis. 1994; 20 (3): 143-149

Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin. by Houston AK and Jones RN published in Diagn. Microbiol. Infect. Dis. 1994; 18 (1): 57-59

Predictive accuracy of disk diffusion test for Proteus vulgaris and Providencia species against five newer orally administered cephalosporins, cefdinir, cefetamet, cefprozil, cefuroxime, and loracarbef. by Biedenbach DJ and Jones RN published in J. Clin. Microbiol. 1994; 32 (2): 559-562

Oxacillin- and quinolone-resistant Staphylococcus aureus in Sao Paulo, Brazil: A multicenter molecular epidemiology study. by Sader HS, Pignatari AC, Hollis RJ, Leme I and Jones RN. published in Infect. Control. Hosp. Epidemiol. 1993; 14 (5): 260-264

Epidemiologic typing of multiply drug-resistant Pseudomonas aeruginosa isolated from an outbreak in an intensive care unit. by Sader HS, Pignatari AC, Leme IL, Burattini MN, Tancresi R, Hollis RJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1993; 17 (1): 13-18

In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5,556 recent clinical isolates from five medical centers. by Sader HS, Jones RN, Washington JA, Murray PR, Gerlach EH, Allen SD and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1993; 17 (2): 143-150

Interlaboratory variations of fluoroquinolone susceptibility testing. An international study to validate the quality of microbiology results reported during the fleroxacin clinical trials. by Jones RN, Erwin ME, Hager HL and Hohl PE published in Diagn. Microbiol. Infect. Dis. 1993; 17 (3): 225-232

Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration result. by Jones RN and Zurenko GE published in Diagn. Microbiol. Infect. Dis. 1993; 17 (4): 313-316

Fluoroquinolone (lomefloxacin) international surveillance trial: A report of 30 months of monitoring in vitro activity. by Jones RN published in Am. J. Med. 1992; 92 (4A): 52S-57S

Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a multicenter, national comparative activity surveillance study. The Ofloxacin Surveillance Group. by Jones RN, Reller LB, Rosati LA, Erwin ME and Sanchez ML published in Diagn. Microbiol. Infect. Dis. 1992; 15 (5): 425-434

Haemophilus test medium interpretive criteria for disk diffusion susceptibility tests with cefdinir, cefetamet, cefmetazole, cefpodoxime, cefdaloxime (RU29246, HR-916 metabolite), and trospectomycin. by Jones RN and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1992; 15 (8): 693-701

In vitro activity of 43 antimicrobial agents tested against ampicillin- resistant enterococci and Gram-positive species resistant to vancomycin. by Yamane N and Jones RN published in Diagn. Microbiol. Infect. Dis. 1991; 14 (4): 337-345

Antimicrobial susceptibility testing trends and accuracy in the United States. A review of the College of American Pathologists Microbiology Surveys, 1972-1989. Microbiology Resource Committee of the College of American Pathologists. by Jones RN and Edson DC published in Arch. Pathol. Lab. Med. 1991; 115 (5): 429-436

Interpretive criteria, quality control guidelines and drug stability studies for susceptibility testing of cefotaxime, cefoxitin, ceftazidime, and cefuroxime against Neisseria gonorrhoeae. by Jones RN, Fuchs PC, Washington JA, Gavan TL, Murray PR, Gerlach EH and Thornsberry C published in Diagn. Microbiol. Infect. Dis. 1990; 13 (6): 499-507

Multicenter in vitro evaluation of SM-7338, a new carbapenem. by Jones RN, Aldridge KE, Allen SD, Barry AL, Fuchs PC, Gerlach EH and Pfaller MA published in Antimicrob. Agents Chemother. 1989; 33 (4): 562-565

Stability of SM-7338, a new carbapenem in mediums recommended for the susceptibility testing of anaerobic bacteria and gonococci. by Jones RN and Gardiner RV published in Diagn. Microbiol. Infect. Dis. 1989; 12 (3): 271-273